Vectura Group PLC (LON:VEC)‘s stock had its “overweight” rating reissued by research analysts at JPMorgan Chase & Co. in a note issued to investors on Thursday. They presently have a GBX 230 ($2.87) price objective on the stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 54.29% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Citigroup Inc. reissued a “buy” rating and issued a GBX 215 ($2.69) price target on shares of Vectura Group PLC in a research note on Thursday, July 28th. Peel Hunt reissued a “buy” rating and issued a GBX 200 ($2.50) price target on shares of Vectura Group PLC in a research note on Thursday, July 28th. FinnCap reissued a “buy” rating and issued a GBX 225 ($2.81) price target on shares of Vectura Group PLC in a research note on Tuesday, August 30th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 242 ($3.02) price target on shares of Vectura Group PLC in a research note on Friday, July 29th. Finally, N+1 Singer reissued a “buy” rating and issued a GBX 208 ($2.60) price target on shares of Vectura Group PLC in a research note on Tuesday, November 22nd. Eight investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of GBX 222.13 ($2.78).

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Vectura Group PLC (LON:VEC) opened at 151.90 on Thursday. The stock’s 50 day moving average price is GBX 138.63 and its 200-day moving average price is GBX 147.84. Vectura Group PLC has a 12 month low of GBX 122.90 and a 12 month high of GBX 200.10.

ILLEGAL ACTIVITY NOTICE: “Vectura Group PLC (VEC) Rating Reiterated by JPMorgan Chase & Co.” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of US and international trademark & copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/28/vectura-group-plc-vec-rating-reiterated-by-jpmorgan-chase-co.html.

In other Vectura Group PLC news, insider Bruno Angelici purchased 80,000 shares of the firm’s stock in a transaction on Monday, September 26th. The stock was bought at an average price of GBX 143 ($1.79) per share, with a total value of £114,400 ($142,928.54). Also, insider Trevor Phillips sold 240,841 shares of the firm’s stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of GBX 139 ($1.74), for a total transaction of £334,768.99 ($418,252.11).

Vectura Group PLC Company Profile

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.

Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.